Intravenous products: News-Medical.net report “Pall Corporation, a global leader in filtration, separation and purification, today announced the launch of the LeukotrapÂ® Affinity Plus Prion and Leukocyte Reduction Filter System. The new blood filter reduces prions and leukocytes in a single step. The Leukotrap® Affinity Plus System is CE marked in accordance with requirements set out in the Medical Devices Directive (93/42/EEC).
Infectious prions (PRPsc) are known to be the causative agent of variant Creutzfeldt-Jakob disease (vCJD). The Pall Leukotrap Affinity Plus System reduces PRPSC prion by >3 LOG on average, based on Western blot methodology. As a primary leukocyte and prion reduction technology, it also facilitates superior hemoglobin recovery, to meet current EU requirements.”